TNFRSF1A mutations and autoinflammatory syndromes

Current Opinion in Immunology

Volumn 12, Issue 4, 2000, Pages 479-486

  Galon, Jérôme ^a   Aksentijevich, Ivona ^a   McDermott, Michael F ^b   O'Shea, John J ^a   Kastner, Daniel L ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYSTEINE; HYBRID PROTEIN; PROTEIN P75; TUMOR NECROSIS FACTOR RECEPTOR;

AUTOIMMUNE DISEASE; DISULFIDE BOND; FEVER; GENE MUTATION; HUMAN; IMMUNOGENETICS; INFLAMMATION; RECURRENT DISEASE; REVIEW; SYSTEMIC DISEASE; T LYMPHOCYTE;

EID: 0034095570     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00124-2     Document Type: Review

References (44)

1. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome Cell. 81:1995;935-946.
2. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A.G., Debatin K.M., Fischer A., de Villartay J.P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1347-1349.
3. Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.-L., Elkon K.B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity N Engl J Med. 335:1996;1643-1649.
4. Nagamine K., Peterson P., Scott H.S., Kudoh J., Minoshima S., Heino M., Krohn K.J.E., Lalioti M.D., Mullis P.E., Antonarakis S.E.et al. Positional cloning of the APECED gene Nat Genet. 17:1997;393-398.
5. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 17:1997;399-403.
6. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., Mansfield E., Gadina M., Karenko L., Pettersson T.et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 97:1999;133-144. This is the first published report of mutations in the gene encoding the p55 TNF receptor in families with dominantly inherited periodic fevers. Mutations were found in patients from several ethnic backgrounds; the term 'TNF-receptor-associated periodic syndrome (TRAPS)' was proposed for this condition. Leukocytes from patients with the C52F mutation were shown to have increased membrane TNFRSF1A and impaired TNFRSF1A ectodomain cleavage upon in vitro stimulation, suggesting an impairment in normal negative homeostatic processes.
7. Hoffman H.M., Wright F.A., Broide D.H., Wanderer A.A., Kolodner R.D. Identification of a locus on chromosome 1q44 for familial cold urticaria Am J Hum Genet. 66:2000;1693-1698.
8. Tromp G., Kuivaniemi H., Raphael S., Ala-Kokko L., Christiano A., Considine E., Dhulipala R., Hyland J., Jokinen A., Kivirikko S.et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16 Am J Hum Genet. 59:1996;1097-1107.
9. Centola M., Aksentijevich I., Kastner D.L. The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases Hum Mol Genet. 7:1998;1581-1588.
10. Drenth J.P.H., van der Meer J.W.M. Periodic fevers enter the era of molecular diagnosis. And they are throwing some light on inflammatory mechanisms. Brit Med J. 320:2000;1091-1092. This editorial highlights recent advances in the molecular analysis of the hereditary periodic fever syndromes.
11. Livneh A., Drenth J.P.H., Klasen I.S., Langevitz P., George J., Shelton D.A., Gumucio D.L., Pras E., Kastner D.L., Pras M., van der Meer J.W.M. Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome: two diseases with distinct clinical, serologic, and genetic features. J Rheumatol. 24:1997;1558-1563.
12. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 90:1997;797-807.
13. A candidate gene for familial Mediterranean fever. Nat Genet. 17:1997;25-31.
14. Centola M., Wood G., Frucht D.M., Galon J., Aringer M., Farrell C., Kingma D.W., Horwitz M.E., Mansfield E., Holland S.M.et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators Blood. 95:2000;3223-3231.
15. Houten S.M., Kuis W., Duran M., de Koning T.J., van Royen-Kerkhof A., Romeijn G.J., Frankel J., Dorland L., de Barse M.M.J., Huijbers W.A.R.et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. Nat Genet. 22:1999;175-177. The hyper-IgD and periodic fever syndrome is a recessively inherited disorder characterized by recurrent fevers, lymphadenopathy, abdominal pain, skin rash and joint pains. Based on the observation of elevated levels of mevalonic acid in the urine of such a patient, the gene encoding mevalonate kinase was screened for mutations. Three missense mutations (H20P, I268T and V377I) were identified; each mutation leads to a reduction in mevalonate kinase protein levels in patient fibroblasts.
16. •]. The authors conducted a genome-wide search in a large panel of families with the hyper-IgD syndrome, ultimately placing the gene on the long arm of chromosome 12. Because the mevalonate kinase gene resides within the candidate interval, it was screened for mutations. Three missense mutations (P165L, I268T and V377I) were identified, as well as a 92-basepair loss at the 5′ end of the gene.
17. Williamson L.M., Hull D., Mehta R., Reeves W.G., Robinson B.H., Toghill P.J. Familial hibernian fever Quart J Med. 51:1982;469-480.
18. McDermott E.M., Smillie D.M., Powell R.J. The clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index and extended family Mayo Clin Proc. 72:1997;806-817.
19. Mulley J., Saar K., Hewitt G., Rüschendorf F., Phillips H., Colley A., Sillence D., Reis A., Wilson M. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet. 62:1998;884-889.
20. Gertz M.A., Petitt R.M., Perrault J., Kyle R.A. Autosomal dominant familial Mediterranean fever-like syndrome with amyloidosis Mayo Clin Proc. 62:1987;1095-1100.
21. Zaks N., Kastner D.L. Clinical syndromes resembling familial Mediterranean fever. Sohar E., Gafni J., Pras M. Familial Mediterranean Fever. 1997;211-215 Freund, London and Tel Aviv.
22. McDermott M.F., Ogunkolade B.W., McDermott E.M., Jones L.C., Wan Y., Quane K.A., McCarthy J., Phelan M., Molloy M.G., Powell R.J.et al. Linkage of familial Hibernian fever to chromosome 12p13 Am J Hum Genet. 62:1998;1446-1451.
23. Loetscher H., Pan Y.-C.E., Lahm H.-W., Gentz R., Brockhaus M., Tabuchi H., Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor Cell. 61:1990;351-359.
24. Schall T.J., Lewis M., Koller K.J., Lee A., Rice G.C., Wong G.H.W., Gatanaga T., Granger G.A., Lentz R., Raab H.et al. Molecular cloning and expression of a receptor for human tumor necrosis factor Cell. 61:1990;361-370.
25. Smith C.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R., Dower S.K., Cosman D., Goodwin R.G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins Science. 248:1990;1019-1023.
26. Pfeffer K., Matsuyama T., Kündig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Krönke M., Mak T.W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73:1993;457-467.
27. Erickson S.L., de Sauvage F.J., Kikly K., Carver-Moore K., Pitts-Meek S., Gillett N., Sheehan K.C.F., Schreiber R.D., Goeddel D.V., Moore M.W. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 372:1994;560-563.
28. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., Charrier K., Morrissey P.J., Ware C.B., Mohler K.M. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation J Immunol. 160:1998;943-952.
29. Vassalli P. The pathophysiology of tumor necrosis factors Annu Rev Immunol. 10:1992;411-452.
30. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H-J., Broger C., Loetscher H., Lesslauer W. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell. 73:1993;431-445.
31. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation Cell. 81:1995;495-504.
32. Engelmann H., Holtmann H., Brakebusch C., Avni Y.S., Sarov I., Nophar Y., Hadas E., Leitner O., Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity J Biol Chem. 265:1990;14497-14504.
33. Watowich S.S., Yoshimura A., Longmore G.D., Hilton D.J., Yoshimura Y., Lodish H.F. Homodimerization and constitutive activation of the erythropoietin receptor Proc Natl Acad Sci USA. 89:1992;2140-2144.
34. Alexander W.S., Metcalf D., Dunn A.R. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity EMBO J. 14:1995;5569-5578.
35. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H.et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B Science. 267:1995;381-383.
36. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils J Exp Med. 172:1990;599-607.
37. Crowe P.D., Walter B.N., Mohler K.M., Otten-Evans C., Black R.A., Ware C.F. A metalloprotease inhibitor blocks shedding of the 80 kD TNF receptor and TNF processing in T lymphocytes J Exp Med. 181:1995;1205-1210.
38. Müllberg J., Durie F.H., Otten-Evans C., Alderson M.R., Rose-John S., Cosman D., Black R.A., Mohler K.M. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol. 155:1995;5198-5205.
39. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity J Biol Chem. 264:1989;11974-11980.
40. Gullberg U., Lantz M., Lindvall L., Olsson I., Himmler A. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutatgenesis of a putative cleavage site in the p55 TNF receptor chain. Eur J Cell Biol. 58:1992;307-312.
41. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K.et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med. 337:1997;141-147.
42. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J.N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis Lancet. 344:1994;1125-1127.
43. Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 337:1997;1029-1035.
44. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J. 10:1991;4025-4031.